We are live on ! Find out more

Cadrenal Therapeutics

CVKD

Market cap $4M

1.12 USD

+0.03

2.75%

At close Updated Sep 22, 4:00 PM EDT

Pre-market

After hours

1.10

-0.02

1.79%

1 day

2.75%

5 days

6.67%

1 month

-28.66%

3 months

-64.78%

6 months

-81.79%

Year to date

-84.72%

1 year

-91.42%

5 years

-98.19%

10 years

-98.19%

About: Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Employees: 5

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference

PONTE VEDRA, Fla., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X.

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated $2 Billion in Peak Annual Revenue Opportunity PONTE VEDRA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced positive feedback from a Type D Meeting with the U.S. Food and Drug Administration (FDA) held on July 28, 2026.

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding Late-breaking Phase 2 CAD-1005 data presented at ISTH support a late-stage portfolio organized around preoperative safety, orphan regulatory acceleration, and postoperative shielding

Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation

Urgent Need for Novel Targets - Recent clinical failure of a competing mechanism highlights urgent need for novel upstream targets, such as 12-LOX, that are being studied to address the root causes of cardio-renal injury Dual-Indication Development and Commercialization Strategy Expands the Clinical Advancement of CAD-1005 to target both Heparin-Induced Thrombocytopenia (HIT) and Cardiac Surgery-Associated Acute Kidney Injury (CSA-AKI) Addresses High-Value Gap in the Acute Care Market –First-in-class positioning in the $1 billion+ U.S. CSA-AKI market following the recent discontinuation of a competitor's late-stage Phase 3 clinical trial for lack of efficacy Global Partnering Potential – Leverages shared in-hospital ICU infrastructure and intravenous (IV) presentation to deliver a critical care asset package PONTE VEDRA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced a consolidation of its multi-indication strategy for its Cardiac Acute Critical Care (CACC) Franchise, with a focus on CAD-1005 for both HIT and CSA-AKI.

Cadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor's Phase 3 Discontinuation

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin Recently presented Phase 2 CAD-1005 data demonstrated a >25% absolute reduction in thrombotic events in patients with heparin-induced thrombocytopenia PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of its clinical portfolio into a Cardiac Acute Critical Care Franchise.

Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade. Oral presentation by Principal Investigator Dr. Steven E.

Cadrenal Therapeutics' Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3 million upfront with up to approximately $5.8 million of potential additional gross proceeds upon the exercise in full of warrants

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Selection highlights the clinical value potential of Cadrenal's first-in-class 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT) First-ever randomized, blinded, placebo-controlled trial in HIT, a life-threatening blood-clotting disorder triggered by an immune reaction to heparin, the most widely used blood thinner in hospitals Phase-3 ready and addresses a peak $2 billion annual revenue potential in the HIT market PONTE VEDRA, Fla., June 24, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company advancing late-stage novel therapies for life-threatening immune and thrombotic conditions, today announced that late-breaking clinical data on its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005 (formerly VLX-1005), have been accepted for a prestigious oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis (ISTH).

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

Company to present Phase 3-ready pipeline, 12-LOX platform, and pediatric rare-disease expansion to global pharmaceutical partners at the 2026 BIO International Convention in San Diego Kawasaki disease is the leading cause of acquired heart disease in children in developed nations. Patients are at risk of forming blood clots in coronary arteries and may require lifelong treatment If the designation is granted and tecarfarin is approved for this indication, Cadrenal would be eligible to receive a Priority Review Voucher—recent open-market valuations for these vouchers have reached into the ~$200 million range PONTE VEDRA, Fla.

Cadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease

See News Rankings

Price charts implemented using Lightweight Charts™